Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 22488662)

1.

Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.

Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S, Carroll WL, Camitta B, Dreyer ZE.

Pediatr Blood Cancer. 2012 Nov;59(5):834-9. doi: 10.1002/pbc.24132. Epub 2012 Apr 5.

2.

Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China.

Li SD, Chen YB, Li ZG, Wu RH, Qin MQ, Zhou X, Jiang J, Zhang RD, Xie J, Ma XL, Zhang R, Wang B, Wu Y, Zheng HY, Wu MY.

Chin Med J (Engl). 2015 Feb 20;128(4):472-6. doi: 10.4103/0366-6999.151085.

3.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.

Salzer WL, Jones TL, Devidas M, Dreyer ZE, Gore L, Winick NJ, Sung L, Raetz E, Loh ML, Wang CY, De Lorenzo P, Valsecchi MG, Pieters R, Carroll WL, Hunger SP, Hilden JM, Brown P.

Pediatr Blood Cancer. 2015 Mar;62(3):414-8. doi: 10.1002/pbc.25311. Epub 2014 Nov 18.

PMID:
25407157
4.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

PMID:
25399948
5.

Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial.

Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A, Uyttebroeck A, Sirvent N, Lutz P, Yakouben K, Munzer M, Röhrlich P, Plantaz D, Millot F, Philippet P, Dastugue N, Girard S, Cavé H, Benoit Y, Bertrandfor Y; Children's Leukemia Group (CLG) of European Organisation for Research and Treatment of Cancer (EORTC).

Haematologica. 2014 Jul;99(7):1220-7. doi: 10.3324/haematol.2014.103507. Epub 2014 Apr 11.

6.

Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.

Nickel RS, Keller F, Bergsagel J, Cooper T, Daves M, Sabnis H, Lew G.

Pediatr Blood Cancer. 2014 May;61(5):810-4. doi: 10.1002/pbc.24892. Epub 2013 Dec 19.

7.

Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.

Hyakuna N, Shimomura Y, Watanabe A, Taga T, Kikuta A, Matsushita T, Kogawa K, Kawakami C, Horikoshi Y, Iwai T, Okamoto Y, Tsurusawa M, Asami K; Japanese Childhood Cancer and Leukemia Study Group (JCCLSG).

J Pediatr Hematol Oncol. 2014 Jan;36(1):22-9. doi: 10.1097/MPH.0000000000000039.

8.

[Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].

Mei YY, Gao C, Cui L, Zhao XX, Zhao W, Li WJ, Wang KL, Jiang J, Zhang RD, Xie J, Shi HW, Wang B, Zhang YH, Ma XL, Zhou X, Wu MY, Li ZG.

Zhonghua Er Ke Za Zhi. 2013 Jun;51(6):467-71. Chinese.

PMID:
24120066
9.

Early deaths in pediatric acute leukemia: a population-based study.

Cheng S, Pole JD, Sung L.

Leuk Lymphoma. 2014 Jul;55(7):1518-22. doi: 10.3109/10428194.2013.850685. Epub 2013 Nov 19.

PMID:
24090501
10.

Prediction of outcome by early response in childhood acute lymphoblastic leukemia.

Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M, Zimmermann M, Attarbaschi A, Niggli F, Schrappe M.

Klin Padiatr. 2013 May;225 Suppl 1:S50-6. doi: 10.1055/s-0033-1337964. Epub 2013 May 22.

PMID:
23700057
11.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S.

Am J Hematol. 2013 Aug;88(8):657-60. doi: 10.1002/ajh.23468. Epub 2013 Jun 5.

PMID:
23640768
12.

Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.

Lee SM, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party.

Ann Hematol. 2013 Aug;92(8):1101-10. doi: 10.1007/s00277-013-1728-y. Epub 2013 Apr 5.

PMID:
23558905
14.

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.

Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.

PMID:
23407458
15.

A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.

Patel S, Liedtke M, Ngo D, Medeiros BC.

Leuk Lymphoma. 2013 Oct;54(10):2231-5. doi: 10.3109/10428194.2013.772606. Epub 2013 Mar 8.

PMID:
23383599
16.

Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group.

Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch M.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1229-33. doi: 10.1002/pbc.24149. Epub 2012 Apr 5.

PMID:
22488718
17.

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.

Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL.

J Clin Oncol. 2012 May 10;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018. Epub 2012 Mar 12.

18.

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M.

Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22.

19.

No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.

Felice MS, Rossi JG, Gallego MS, Alfaro EM, Zubizarreta PA, Fraquelli LE, Alonso CN, Guitter MR, Scopinaro MJ.

Pediatr Blood Cancer. 2011 Jul 15;57(1):47-55. doi: 10.1002/pbc.23097. Epub 2011 Mar 10.

PMID:
21394895
20.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L, Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhédin N, Delannoy A, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Haematologica. 2011 Feb;96(2):245-52. doi: 10.3324/haematol.2010.027862. Epub 2010 Oct 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk